non-small cell lung cancer

next step ladder climb succeed win
Biotech

Nuvalent races to FDA to challenge Pfizer for lung cancer market

Nuvalent has reported phase 1/2 lung cancer data, teeing up talks about a filing that could establish neladalkib as a challenger to Pfizer’s Lorbrena.
Nick Paul Taylor Nov 17, 2025 7:45am
Blue race track
Favicon Fierce Pharma

Merck grows more ambitious about 'workhorse' TROP2 ADC

Oct 20, 2025 4:00pm
Akeso
Favicon Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

Oct 19, 2025 10:45am
Cancer mutation precision medicine oncology targeted

ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR

Oct 19, 2025 4:15am
Summit
Favicon Fierce Pharma

Summit's global PD-1xVEGF data show new promising OS trend

Sep 7, 2025 3:30am
Akeso
Favicon Fierce Pharma

Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time

Aug 26, 2025 11:36am